Mesoblast Limited announced changes to its Board of Directors’ leadership roles effective January 1, 2026, aligning governance with its transition from a development-stage biotech to a revenue-generating commercial company in the wake of its first U.S. FDA product approval and market launch. The board changes were foreshadowed at the company’s recent Annual General Meeting and reflect a periodic review of board composition and leadership strategy.
Jane Bell, who served as Chair during Mesoblast’s transformational period, will retire from the role but remain on the board as a non-executive director, allowing her to continue contributing strategic insight while making way for fresh leadership.
The board unanimously appointed Philip Facchina as the new non-executive Chair. Facchina, who joined Mesoblast’s board in March 2021, brings more than 40 years of experience in corporate strategy, finance and business development across healthcare and other industries. His appointment is intended to reinforce governance as the company focuses on commercial execution.
In addition, Lyn Cobley was named Chair of the Audit and Risk Committee, bringing extensive corporate finance and governance experience from roles with major global institutions. William Burns remains Vice-Chair of the board and Chair of the Nomination and Remuneration Committee, ensuring continuity in leadership and oversight functions.
Mesoblast said these leadership updates support its commitment to sound governance and a high-performing board with the right mix of expertise and perspectives as it seeks to deepen commercial capabilities, particularly in the United States, over the next 12 months.
